Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients.

Malignant hyperthermia (MH) is a pharmacogenetical complication of general anesthesia resulting from abnormal Ca2+-induced Ca2+ release (CICR) via the type 1 ryanodine receptor (RyR1) in skeletal muscles. In this study, we analyzed the genomic DNAs prepared for determination of all the 106 exons of the RyR1 gene from blood samples donated by two MH patients with extremely high CICR rates in their biopsied skeletal muscles and a clear history of MH incidence. Two novel point mutations were found in the exons 96 and 101 with alterations in the coded amino acids within the C-terminal channel region, i.e., Pro4668 to Ser and Leu4838 to Val. The latter mutation was found in both MH patients. Rabbit RyR1 channels carrying corresponding mutations were expressed in CHO cells for functional assay. It was found that the L to V but not the P to S mutation of the RyR1 resulted in enhanced Ca2+ release activity. These results indicate that the L4838V mutation is responsible for the MH incidence. The L4838V mutation is unique because it is the mutation first found within a hydrophobic transmembrane segment of the channel region and should provide further information on the function of the RyR1 as well as for genetic diagnosis of MH.

[1]  W. Strauss.  Preparation of genomic DNA from mammalian tissue. , 2001, Current protocols in neuroscience.

[2]  N. Romero,et al.  An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. , 2000, Human molecular genetics.

[3]  K. Stowell,et al.  A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. , 2000, Human molecular genetics.

[4]  T. McCarthy,et al.  Ryanodine receptor mutations in malignant hyperthermia and central core disease , 2000, Human mutation.

[5]  N. Pollock,et al.  Malignant hyperthermia in infancy and identification of novel RYR1 mutation. , 2000, British journal of anaesthesia.

[6]  F. Salvatore,et al.  Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family , 2000, European Journal of Human Genetics.

[7]  F. Lehmann-Horn,et al.  Genetics and pathogenesis of malignant hyperthermia , 2000, Muscle & nerve.

[8]  E. Katayama,et al.  Further Characterization of the Type 3 Ryanodine Receptor (RyR3) Purified from Rabbit Diaphragm* , 1999, The Journal of Biological Chemistry.

[9]  M. Lehane,et al.  A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Haug.  Malignant hyperthermia and central core disease: Disorders of Ca2+ release channels , 1999 .

[11]  J. Keen,et al.  Cloning and characterization of fiber type-specific ryanodine receptor isoforms in skeletal muscles of fish. , 1998, The American journal of physiology.

[12]  D. Maclennan,et al.  Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. , 1998, The American journal of medicine.

[13]  J. Nakai,et al.  Molecular cloning and characterization of a human brain ryanodine receptor 1 , 1997, FEBS letters.

[14]  S. Grinstein,et al.  Caffeine and Halothane Sensitivity of Intracellular Ca2+ Release Is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease* , 1997, The Journal of Biological Chemistry.

[15]  H. Ando,et al.  An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans. , 1997, Journal of molecular biology.

[16]  P. Allen,et al.  The human cardiac muscle ryanodine receptor-calcium release channel: identification, primary structure and topological analysis. , 1996, The Biochemical journal.

[17]  M. Phillips,et al.  The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. , 1996, Genomics.

[18]  L. Ottini,et al.  Alpha and beta isoforms of ryanodine receptor from chicken skeletal muscle are the homologues of mammalian RyR1 and RyR3. , 1996, The Biochemical journal.

[19]  M. Gossen,et al.  Co-regulation of two gene activities by tetracycline via a bidirectional promoter. , 1995, Nucleic acids research.

[20]  S. Mammarella,et al.  The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues , 1995, The Journal of cell biology.

[21]  M. Endo,et al.  Primary structure and distribution of ryanodine-binding protein isoforms of the bullfrog skeletal muscle. , 1994, The Journal of biological chemistry.

[22]  T. Hosoya,et al.  Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster , 1994, FEBS letters.

[23]  P. Iredale,et al.  Increases in intracellular calcium via activation of an endogenous P2‐purinoceptor in cultured CHO‐K1 cells , 1993, British journal of pharmacology.

[24]  M. Phillips,et al.  A mutation in the human ryanodine receptor gene associated with central core disease , 1993, Nature Genetics.

[25]  J. Nakai,et al.  Primary structure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brain , 1992, FEBS letters.

[26]  B. Britt,et al.  Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. , 1992, Genomics.

[27]  M. Endo,et al.  Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia , 1992 .

[28]  K. Otsu,et al.  Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. , 1991, Science.

[29]  J. Nakai,et al.  Primary structure and functional expression from cDN A of the cardiac ryanodine receptor/calcium release channel , 1990, FEBS letters.

[30]  H. Willard,et al.  Molecular cloning of cDNA encoding the Ca2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. , 1990, The Journal of biological chemistry.

[31]  M. Phillips,et al.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia , 1990, Nature.

[32]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2 , 1990, Nature.

[33]  M. Phillips,et al.  Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. , 1990, The Journal of biological chemistry.

[34]  H. Takeshima,et al.  Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor , 1989, Nature.

[35]  M. Endo,et al.  Ca-induced Ca release in malignant hyperthermia-susceptible pig skeletal muscle. , 1989, The American journal of physiology.

[36]  M. Endo,et al.  CHANGES IN THE Ca-INDUCED Ca RELEASE MECHANISM IN THE SARCOPLASMIC RETICULUM OF THE MUSCLE FROM A PATIENT WITH MALIGNANT HYPERTHERMIA , 1983 .

[37]  J. Garnier,et al.  Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. , 1978, Journal of molecular biology.

[38]  B. Britt,et al.  Metabolic error of muscle metabolism after recovery from malignant hyperthermia. , 1970, Lancet.

[39]  H. Willard,et al.  Molecular Cloning of cDNA Encoding the Ca 2 + Release Channel ( Ryanodine Receptor ) of Rabbit Cardiac Muscle Sarcoplasmic Reticulum * , 2001 .

[40]  J. Nickoloff,et al.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. , 1992, Analytical biochemistry.

[41]  M. Endo.  Mechanism of Action of Caffeine on the Sarcoplasmic Reticulum of Skeletal Muscle , 1975 .